Evidence map›Paper›PMID 39836471›Full record

ArticleThe Journal of clinical investigation2025

Mycobacterium tuberculosis resisters despite HIV exhibit activated T cells and macrophages in their pulmonary alveoli.

Monica Dallmann-Sauer, Vinicius M Fava, Stephanus T Malherbe, Candice E MacDonald, Marianna Orlova, Elouise E Kroon, Aurélie Cobat, Stéphanie Boisson-Dupuis, Eileen G Hoal, Laurent Abel and 5 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Diverse infection models demonstrate robust resistance ofbioRxiv : the preprint server for biology · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Advances in Single-Cell Sequencing for Infectious Diseases: Progress and Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Monica Dallmann-SauerProgram in Infectious Diseases and Immunity in Global Health, The Research Institute of the McGill University Health Centre, Montreal, Canada.
Vinicius M FavaProgram in Infectious Diseases and Immunity in Global Health, The Research Institute of the McGill University Health Centre, Montreal, Canada.
Stephanus T MalherbeSouth African Medical Research Council Centre for Tuberculosis Research; Biomedical Research Institute, Division of Immunology, Department of Biomedical Sciences and.
Candice E MacDonaldSouth African Medical Research Council Centre for Tuberculosis Research; Biomedical Research Institute, Division of Immunology, Department of Biomedical Sciences and.
Marianna OrlovaProgram in Infectious Diseases and Immunity in Global Health, The Research Institute of the McGill University Health Centre, Montreal, Canada.
Elouise E KroonSouth African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Aurélie CobatSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, USA.
Stéphanie Boisson-DupuisSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, USA.
Eileen G HoalSouth African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Laurent AbelSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, USA.
Marlo MöllerSouth African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Jean-Laurent CasanovaSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, USA.
Gerhard WalzlSouth African Medical Research Council Centre for Tuberculosis Research; Biomedical Research Institute, Division of Immunology, Department of Biomedical Sciences and.
Nelita Du PlessisSouth African Medical Research Council Centre for Tuberculosis Research; Biomedical Research Institute, Division of Immunology, Department of Biomedical Sciences and.
Erwin SchurrProgram in Infectious Diseases and Immunity in Global Health, The Research Institute of the McGill University Health Centre, Montreal, Canada.

Funding

IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) - SARS-CoV-2 RELATED RESEARCH75N93019C00070 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI URDAHL, KEVIN · 2019 to 2025
$86.6M
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Pharmacology & ImmunoPathology (PIP) CoreU19AI162568 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI EHRT, SABINE · 2021 to 2025
$13.0M
Human genetics of TB resistance in HIV-infected personsR01AI124349 · NIAID · MCGILL UNIVERSITY HEALTH CTR RES INST · PI SCHURR, ERWIN · 2016 to 2020
$8.0M
NCATS NIH HHS UL1 TR001866NIAID NIH HHS 75N93019C00070NIAID NIH HHS R01 AI124349NIAID NIH HHS U19 AI162568
6 · The paper itself

Abstract

BACKGROUNDNatural resistance to Mycobacterium tuberculosis (Mtb) infection in some people with HIV (PWH) is unexplained.METHODSWe performed single cell RNA-sequencing of bronchoalveolar lavage cells, unstimulated or ex vivo stimulated with Mtb, for 7 PWH who were tuberculin skin test (TST) and IFN-γ release assay (IGRA) positive (called LTBI) and 6 who were persistently TST and IGRA negative (called resisters).RESULTSAlveolar macrophages (AM) from resisters displayed a baseline M1 macrophage phenotype while AM from LTBI did not. Resisters displayed alveolar lymphocytosis, with enrichment of all T cell subpopulations including IFNG-expressing cells. In both groups, mycobactericidal granulysin was expressed almost exclusively by a T cell subtype that coexpressed granzyme B, perforin and NK cell receptors. These poly-cytotoxic T lymphocytes (poly-CTL) overexpressed activating NK cell receptors and were increased in resister BAL. Following challenge with Mtb, only intraepithelial lymphocyte-like cells from LTBI participants responded with increased transcription of IFNG. AM from resisters responded with a stronger TNF signature at 6 hours after infection while at 24 hours after infection, AM from LTBI displayed a stronger IFN-γ signature. Conversely, at 24 hours after infection, only AM from resisters displayed an upregulation of MHC class I polypeptide-related sequence A (MICA) transcripts, which encode an activating ligand for poly-CTL.CONCLUSIONThese results suggest that poly-CTL and M1-like pre-activated AM mediate the resister phenotype in PWH.FUNDINGNational Institutes of Health. Canadian Institutes of Health Research. Digital Research Alliance of Canada. French National Research Agency. French National Agency for Research on AIDS and Viral Hepatitis. St. Giles Foundation. General Atlantic Foundation. South African Medical Research Council Centre for Tuberculosis Research.

Indexed as

HIV-1HIV InfectionsLatent TuberculosisLymphocyte ActivationMacrophages, AlveolarMycobacterium tuberculosisPulmonary AlveoliAdultAntigens, Differentiation, T-LymphocyteFemaleHumansInterferon-gammaMaleMiddle AgedT-Lymphocytes, CytotoxicTuberculosis, PulmonaryAntigens, Differentiation, T-LymphocyteGNLY protein, humanInterferon-gammaInfectious diseaseMacrophagesT cellsTuberculosis

Identifiers

PMID39836471
PMCPMC11957701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.